Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9981)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 21, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol 2016; 22(27): 6114-6126 [PMID: 27468204 DOI: 10.3748/wjg.v22.i27.6114] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i27/6114.htm |
| Number | Citing Articles |
| 1 |
Yu. S. Taskaeva, N. P. Bgatova. Ultrastructural Changes in Hepatocellular Carcinoma-29 Cells after Treatment with Lithium Carbonate. Bulletin of Experimental Biology and Medicine 2019; 167(1): 87 doi: 10.1007/s10517-019-04467-3
|
| 2 |
Takeshi Kinoshita, Hajime Higuchi, Ayano- Kabashima-, Gen Sakai, Yasuo Hamamoto, Hiromasa Takaishi, Takanori Kanai. Analysis of Sensitivity and Cell Death Pathways Mediated by Anti-cancer Drugs Using Three-dimensional Culture System. International Journal of Cancer Research 2017; 14(1): 1 doi: 10.3923/ijcr.2018.1.12
|
| 3 |
Liliana Montella, Federica Sarno, Annamaria Ambrosino, Sergio Facchini, Maria D’Antò, Maria Maddalena Laterza, Morena Fasano, Ermelinda Quarata, Raffaele Angelo Nicola Ranucci, Lucia Altucci, Massimiliano Berretta, Gaetano Facchini. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021; 10(8): 1909 doi: 10.3390/cells10081909
|
| 4 |
Yan-Qiong Zhang, Yan Shen, Ming-Mei Liao, Xia Mao, Gu-Jie Mi, Chen You, Qiu-Yan Guo, Wei-Jie Li, Xiao-Yue Wang, Na Lin, Thomas J. Webster. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms. Nanomedicine: Nanotechnology, Biology and Medicine 2019; 15(1): 86 doi: 10.1016/j.nano.2018.09.002
|
| 5 |
Chun-I Wang, Pei-Ming Chu, Yi-Li Chen, Yang-Hsiang Lin, Cheng-Yi Chen. Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. International Journal of Molecular Sciences 2021; 22(24): 13627 doi: 10.3390/ijms222413627
|
| 6 |
Lu Bai, Siwen Sun, Wenmei Su, Chaoqun Chen, Yuesheng Lv, Jinrui Zhang, Jinyao Zhao, Man Li, Yangfan Qi, Wenjing Zhang, Yang Wang. Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1007006
|
| 7 |
Kishore Kumar Jella, Zhentian Li. Role of Transcription Factors in Gastrointestinal Malignancies. 2017; : 449 doi: 10.1007/978-981-10-6728-0_34
|
| 8 |
Xiao-xiao He, Liang-liang Shi, Meng-jun Qiu, Qiu-ting Li, Meng-meng Wang, Zhi-fan Xiong, Sheng-li Yang. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochemical and Biophysical Research Communications 2018; 504(4): 878 doi: 10.1016/j.bbrc.2018.08.203
|
| 9 |
Ruonan Chen, Zixiong Zhou, Yi Chen, Aimin Huang, Lihong Chen. Evaluation of transcriptomic molecular classification, biological behavior, and clinicopathological features in hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2023; 23(1): 71 doi: 10.1080/14737159.2023.2169072
|
| 10 |
Tarik Demir, Sunyoung S. Lee, Ahmed O. Kaseb. Mechanisms and Therapy of Liver Cancer. Advances in Cancer Research 2021; 149: 257 doi: 10.1016/bs.acr.2020.12.001
|
| 11 |
Seyed Mohammadmahdi Meybodi, Pouria Rezaei, Niki Faraji, Kiyarash Jamehbozorg, Sara Ashna, Fatemeh Shokri, Pouya Goleij, Saeed Moradi, Mahdis Kashian, Reza Arefnezhad, Amirhossein Sahebkar. Curcumin and its novel formulations for the treatment of hepatocellular carcinoma: New trends and future perspectives in cancer therapy. Journal of Functional Foods 2023; 108: 105705 doi: 10.1016/j.jff.2023.105705
|
| 12 |
Xiufeng Liu, Shukui Qin. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. The Oncologist 2019; 24(S1): S3 doi: 10.1634/theoncologist.2019-IO-S1-s01
|
| 13 |
Gokhan Yildiz. Integrated multi‑omics data analysis identifying novel drug sensitivity‑associated molecular targets of hepatocellular carcinoma cells. Oncology Letters 2018; doi: 10.3892/ol.2018.8634
|
| 14 |
Wei-xun Chen, Gan-xun Li, Zheng-nan Hu, Peng Zhu, Bi-xiang Zhang, Ze-yang Ding. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. Medicine 2019; 98(45): e17832 doi: 10.1097/MD.0000000000017832
|
| 15 |
Wenfeng Liu, Bing Quan, Shenxin Lu, Bei Tang, Miao Li, Rongxin Chen, Zhenggang Ren, Xin Yin. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.771045
|
| 16 |
Ioannis A Ziogas, Georgios Tsoulfas. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World Journal of Clinical Oncology 2017; 8(3): 203-213 doi: 10.5306/wjco.v8.i3.203
|
| 17 |
Peiyi Xie, Lei Guo, Bo Zhang, Yongfeng Xu, Qi Song, Hongcheng Shi, Qinghai Ye, Hui Li, Yongsheng Xiao. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.911202
|
| 18 |
Wen-Hui Luo, Shao-Jun Li, Xue-Feng Wang. Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature. World Journal of Gastrointestinal Oncology 2023; 15(11): 2033-2040 doi: 10.4251/wjgo.v15.i11.2033
Abstract(333) |
Core Tip(327) |
Full Article(HTML)(984)
|
Full Article with Cover (PDF)-5685K(51)
|
Full Article (Word)-2654K(15)
|
Audio-2199K(0)
|
Peer-Review Report-234K(37)
|
Answering Reviewers-101K(37)
|
Full Article (PDF)-5392K(53)
|
Full Article (XML)-87K(35)
|
Times Cited (0)
|
Total Visits (3562)
|
Open
|
| 19 |
Maryam Tahmasebi Birgani, Vinicio Carloni. Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. International Journal of Molecular Sciences 2017; 18(2): 405 doi: 10.3390/ijms18020405
|
| 20 |
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang. Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology 2016; 22(41): 9069-9095 doi: 10.3748/wjg.v22.i41.9069
|
| 21 |
Matti Sällberg, Anna Pasetto. Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00552
|
| 22 |
Le Quang Thao, Changkyu Lee, Bomi Kim, Sungin Lee, Tae Hwan Kim, Jong Oh Kim, Eun Seong Lee, Kyung Taek Oh, Han-Gon Choi, Sun Dong Yoo, Yu Seok Youn. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids and Surfaces B: Biointerfaces 2017; 152: 183 doi: 10.1016/j.colsurfb.2017.01.017
|
| 23 |
Dashuai Yang, Yang Su, Fangrui Zhao, Chen Chen, Kailiang Zhao, Xiangyun Xiong, Youming Ding. A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.914192
|